Vanessa Favasuli
Overview
Explore the profile of Vanessa Favasuli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morelli E, Ribeiro C, Rodrigues S, Gao C, Socciarelli F, Maisano D, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40053701
Purpose: In multiple myeloma (MM), tumor cells reprogram metabolic pathways to sustain growth and monoclonal immunoglobulin production. This study examines acetyl-CoA carboxylase 1 (ACC1), the enzyme driving the rate-limiting step...
2.
Todoerti K, Ronchetti D, Puccio N, Silvestris I, Favasuli V, Amodio N, et al.
Cancers (Basel)
. 2021 Nov;
13(21).
PMID: 34771679
The biological impact of long non-coding RNAs (lncRNAs) in multiple myeloma (MM) is becoming an essential aspect of the investigation, which may contribute to understanding the disease's complex pathobiology, providing...
3.
Todoerti K, Taiana E, Puccio N, Favasuli V, Lionetti M, Silvestris I, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638381
Mechanisms underlying the pathophysiology of primary Plasma Cell Leukemia (pPCL) and intramedullary multiple myeloma (MM) need to be further elucidated, being potentially relevant for improving therapeutic approaches. In such a...
4.
Taiana E, Favasuli V, Ronchetti D, Morelli E, Tassone P, Viglietto G, et al.
Methods Mol Biol
. 2021 Jun;
2348:157-166.
PMID: 34160805
Despite substantial advancements have been achieved in the identification of long noncoding RNA (lncRNA) molecules, many challenges still remain into their functional characterization. Loss-of-function approaches are needed to study oncogenic...
5.
Sacco A, Federico C, Todoerti K, Ziccheddu B, Palermo V, Giacomini A, et al.
Blood
. 2021 Jun;
138(18):1705-1720.
PMID: 34077955
Alterations in KRAS have been identified as the most recurring somatic variants in the multiple myeloma (MM) mutational landscape. Combining DNA and RNA sequencing, we studied 756 patients and observed...
6.
Todoerti K, Ronchetti D, Favasuli V, Maura F, Morabito F, Bolli N, et al.
Haematologica
. 2021 May;
107(4):921-932.
PMID: 33951891
DIS3 gene mutations occur in roughly 10% of patients with multiple myeloma (MM); furthermore, DIS3 expression can be affected by monosomy 13 and del(13q), which occur in approximately 40% of...
7.
Sacco A, Federico C, Giacomini A, Caprio C, Maccarinelli F, Todoerti K, et al.
Blood
. 2020 Nov;
137(18):2495-2508.
PMID: 33197938
The human fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) axis deregulation is largely involved in supporting the pathogenesis of hematologic malignancies, including Waldenström macroglobulinemia (WM). WM is still an incurable...
8.
Ronchetti D, Todoerti K, Vinci C, Favasuli V, Agnelli L, Manzoni M, et al.
Cancers (Basel)
. 2020 Mar;
12(4).
PMID: 32218309
The biological impact of long non-coding RNAs (lncRNAs) in multiple myeloma (MM) is becoming an important aspect of investigation, which may contribute to the understanding of the complex pathobiology of...
9.
Ronchetti D, Favasuli V, Monti P, Cutrona G, Fabris S, Silvestris I, et al.
Noncoding RNA
. 2020 Mar;
6(1).
PMID: 32182990
The biological role and therapeutic potential of long non-coding RNAs (lncRNAs) in chronic lymphocytic leukemia (CLL) are still open questions. Herein, we investigated the significance of the lncRNA NEAT1 in...
10.
Lionetti M, Barbieri M, Favasuli V, Taiana E, Fabris S, Favoino C, et al.
Hematol Oncol
. 2020 Feb;
38(3):406-408.
PMID: 32097987
No abstract available.